Summary

Other Scenarios:

Buyer: Barr Pharmaceuticals, Inc. (BRL) Last Price: 51.55 Market Cap.: 5.48B
Target: KOS Pharmaceuticals, Inc. (KOSP) Last Price: 78.00 Market Cap.: 3.72B

Lines of Business Summary:

Product Summary:

Overlap & Complementary Sectors

Sector Buyer Target # of Focused Companies
*Healthcare 870
Biopharmaceuticals 330
Medical Devices 247
Outsourced Services   66

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Sample Products in Similar Lines of Business

Sample Products in Complementary Lines of Business
Buyer (Total: 117)
  • Diphenhydramine Hydrochloride
  • Fexofenadine Hydrochloride (12 Hours Extended Release)
  • Fexofenadine Hydrochloride
  • Fexofenadine/Pseudoephedrine
Target (Total: 27)
  • Cardizem LA (Diltiazem Hydrochloride)
  • Niaspan (Niacin)
  • KS 01-018
  • Reverse-D4F
Buyer
  • ViaSpan (Belzer UW)
  • ParaGard T 380A
Target
  • Breath-Actuated Inhaler (BAI)
  • Solid-Dose Drug Delivery System

Business Relationship Summary:

Top Key Suppliers

Top Key Customers
Buyer (Total: 2)
  • Mack-Cali Realty Corp. (CLI)
  • Common Sense Ltd.
Target (Total: 3)
  • Barr Pharmaceuticals, Inc. (BRL)
  • Biovail Corporation (USA) (BVF)
  • Inyx, Inc. (IYXI)
Buyer (Total: 7)
  • McKesson Corporation (MCK)
  • Cardinal Health, Inc. (CAH)
  • AmerisourceBergen Corp. (ABC)
  • Walgreen Company (WAG)
Target (Total: 1)
  • Government - United States

Key Financial Summary:

Key Metrics

  Buyer Target
Number of Employees 2,040 1,361
Revenue Per Employee 653,496.3 710,573.3
Total Revenue 332.4 240.9
Total Expenses 219.2 190.1
Other Revenue 31.9 0.0
Cost of Revenue 81.7 28.3
SG&A Expense 97.5 127.7
Research & Development 40.0 34.2
Other Operating Expense 0.0 0.0
Operating Income 113.2 50.8
Unusual Income 0.0 0.0
LT Debt to Capital 0.42 3.68
Fwd P/E 16.27 42.16
Fwd P/Rev 3.47 4.27
Book Value 1,764.0 786.2
Curr Portion of LTD/Cap Lease 8.5 0.1

Individual Company Summary

Focused

Buyer

Focused (): *Healthcare > Biopharmaceuticals

Target

Focused (): *Healthcare > Biopharmaceuticals > Cardiovascular System

Business Description

Buyer

Barr Pharmaceuticals, Inc. is primarily a holding company. The Company's subsidiaries, Barr Laboratories, Inc. and Duramed Pharmaceuticals, Inc., develop, manufacture and market generic and proprietary pharmaceutical products, respectively. It operates in two business segments. In the generic pharmaceutical segment, it manufactures and distributes approximately 150 different dosage forms and strengths of approximately 75 different generic pharmaceutical products, including 22 oral contraceptive products that represent the largest category of its generic product portfolio. In the proprietary pharmaceutical segment, the Company manufactures and distributes 19 proprietary pharmaceutical products, largely concentrated in the women's healthcare therapeutic category. These products include SEASONALE and SEASONIQUE extended-cycle oral contraceptive products, and Cenestin (synthetic conjugated estrogens, A) and ENJUVIA (synthetic conjugated estrogens, B) line of hormone therapy products.

Target

Kos Pharmaceuticals, Inc. (Kos) is a fully integrated specialty pharmaceutical company engaged in the development and commercialization of prescription products for the treatment of chronic cardiovascular, metabolic and respiratory diseases. Kos manufactures its lead products, Niaspan and Advicor, and markets them directly through its own sales force and co-promotion partners in the United States, through its commercialization partner in Canada and through its commercialization partner and license arrangements outside of the United States, Canada and Japan. In December 2006, Abbott Laboratories acquired 91.4% of Kos Pharmaceuticals, Inc.

Deal Summary

Key Ratios

  Buyer Target
Gross Margin % 73.53 87.9
Operating Margin % 35.46 11.48
Quick Ratio 4.09 2.61
Current Ratio 5.08 2.97
Coverage Ratio 0.04 0.19
Total Assets 2,068.4 1,090.0
Return on Equity % 17.35 8.73
Return on Assets % 14.79 6.3
Cash+ ST Inv. Per Share 6.97 10.8
Total Debt 15.9 30.1
Total Debt to Equity % 0.9 3.83
Total Debt to Tangible Equity % 1.28 5.2
Debt to Asset % 0.77 2.76

Product Summary

Sector Buyer Target
*Healthcare
Biopharmaceuticals
Allergies
The Allergies Subsector includes therapeutics that treat exaggerated immune reaction induced by exposure to a foreign substance.
  
Cardiovascular System
The Cardiovascular System Subsector includes therapeutics that treat disorders affecting the heart and blood vessels.
Dermatology
The Dermatology Subsector includes therapeutics that treat disorders affecting the skin.
  
Digestive System
The Digestive System Subsector includes therapeutics that treat disorders affecting the digestive system.
Endocrinology/Metabolism
The Endocrinology/Metabolism Subsector includes therapeutics that treat metabolic disorders and conditions resulting from the dysfunction of hormone secreting glands.
Hematology
The Hematology Subsector includes therapeutics that treat blood-based diseases and disorders.
Immunology
The Immunology Subsector includes therapeutics that treat disorders affecting the immune system.
Infectious Diseases
The Infectious Diseases Subsector includes therapeutics that treat diseases caused by the invasion and reproduction of microorganisms in the body.
  
Musculoskeletal System
The Musculoskeletal System Subsector includes therapeutics that treat disorders of the bones, joints, ligaments, tendons, and soft tissue involved with them.
  
Neurology
The Neurology Subsector includes therapeutics that treat disorders of the central nervous system, including the brain, spinal cord, and nerves.
  
Obstetrics/Gynecology
The Obstetrics/Gynecology Subsector includes therapeutics that treat female genital disorders, pregnancy, and childbirth.
Oncology
The Oncology Subsector includes therapeutics that treat and manage various types of cancer and related complications.
  
Ophthalmology
The Ophthalmology Subsector includes therapeutics that treat eye disorders, infections, inflammations and irritations.
  
Pain Management
The Pain Management Subsector includes therapeutics that treat and management pain.
  
Respiratory System
The Respiratory System Subsector includes therapeutics that treat disorders affecting both the upper and lower respiratory tract, including the nose, throat, larynx, trachea, bronchi, and lungs.
Surgery
The Surgery Subsector includes therapeutics that treat complications associated with surgical procedures.
  
Toxicology
The Toxicology Subsector includes therapeutics that treat harmful effects from exposure to toxic substances; narcotics, nicotine and alcohol withdrawal therapeutics are also included in this sector.
  
Urology
The Urology Subsector includes therapeutics that treat diseases of the kidney, urinary tract, bladder, and the male reproductive system.
  
Weight Management
The Weight Management Subsectors includes herapeutics that treat and manage weight disorders.
Wound Management
The Wound Management Subsector includes therapeutics that treat cuts, abrasions, and burns from trauma or diseases.
  
Medical Devices
Drug Delivery
The Drug Delivery Subsector includes medical devices that facilitate the delivery of medications through different anatomical entryways, including blood vessels, skin, the mouth, and the lungs. Common devices in this sector include vascular access catheters, needles, implants, and inhalers.
  
General Surgery
The General Surgery Subsector includes medical devices that perform general, non-specialty surgeries; these devices are often general in scope and are used in procedures involving various parts of the body.
  
Obstetrics/Gynecology
The Obstetrics/Gynecology Subsector includes medical devices that diagnose and treat female reproductive diseases; devices used to care for women during pregnancy, childbirth, and the post-partum period are also included in this sector.
  
Outsourced Services  
Drug Delivery Technology
The Drug Delivery Technology Subsector includes companies that develop novel delivery methods for therapeutics.
  

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Product Details

Sector Buyer Target
*Healthcare
Biopharmaceuticals
Allergies  
Upper Respiratory  
Antihistamines
Therapeutics that inhibit the inflammation by blocking the action of histamines on tissues.

Buyer Products:

  • Diphenhydramine Hydrochloride
  • Fexofenadine Hydrochloride (12 Hours Extended Release)
  • Fexofenadine Hydrochloride
  
Antihistamines/Decongestants
Therapeutics that block the inflammatory action of histamines and relieve or prevent coughs.

Buyer Products:

  • Fexofenadine/Pseudoephedrine
  
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress inflammation using a steroidal compound.

Buyer Products:

  • Triamcinolone Acetonide Nasal Spray
  
Cardiovascular System
Heart Disorders
Angina  
Calcium Channel Blocking Agents
Therapeutics that treat chest pains by preventing the entry of calcium into heart muscle cells.

Target Products:

  • Cardizem LA (Diltiazem Hydrochloride)
  
Arrhythmia  
Sodium Channel Blocking Agents
Therapeutics that treat abnormal rhythm of the heart by preventing the entry of sodium into heart muscle cells.

Buyer Products:

  • Flecainide Acetate
  
Sodium Channel Blocking Agents/Potassium Channel Blocking Agents
Therapeutics that treat abnormal rhythm of the heart by preventing the entry of sodium and potassium into heart muscle cells.

Buyer Products:

  • Amiodarone Hydrochloride
  
Heart Failure (HF)  
Complications  
Edema  
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat the accumulation of fluid by increasing the excretion of water and sodium, but not potassium in urine.

Buyer Products:

  • Amiloride Hydrochloride/Hydrochlorothiazide
  • Triamterene/Hydrochlorothiazide
  
Myocardial Infarction (MI)
Free Fatty Acid Inhibitors
Therapeutics that treat irreversible damage to the heart muscle by inhibiting the release of fatty acids from adipose tissue.

Buyer Products:

  • Niaspan (Niacin)
  • Niacin Extended-Release

Target Products:

  • Niaspan (Niacin)
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat irreversible damage to the heart muscle by preventing the synthesis of cholesterol.

Buyer Products:

  • Pravastatin Sodium
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of heart and circulatory system disorders in early stages of clinical research where human subject is involved.

Target Products:

  • KS 01-018
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of heart and circulatory system disorders in very early stages of research where no human subject is involved.

Target Products:

  • Reverse-D4F
  
Vascular Disorders
Atherosclerosis
Free Fatty Acid Inhibitors
Therapeutics that treat the narrowing or hardening of arteries by inhibiting the release of fatty acids from adipose tissue.

Buyer Products:

  • Niaspan (Niacin)

Target Products:

  • Niaspan (Niacin)
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat the narrowing or hardening of the arteries by preventing the synthesis of cholesterol.

Buyer Products:

  • Pravastatin Sodium
  
Deep Vein Thrombosis (DVT)  
Anticoagulating Agents (Anticoagulants)  
Thrombin Inhibitors
Therapeutics that prevent or treat clots in blood vessels by preventing blood clots from forming.

Buyer Products:

  • Warfarin Sodium
  
Hypertension
Angiotensin II Receptor Antagonists
Therapeutics that treat high blood pressure by blocking the angiotensin II receptor.

Target Products:

  • Teveten (Eprosartan Mesylate)
  
Angiotensin II Receptor Antagonists/Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by blocking the angiotensin II receptor and increasing the excretion of sodium ions, potassium ions, and water through urine.

Target Products:

  • Teveten HCT (Eprosartan/Hydrochlorothiazide)
  
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle.

Buyer Products:

  • Duramed Zebeta (Bisoprolol Fumarate)
  
Beta Receptor Blocking Agents (Beta Blockers)/Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle and increasing the excretion of sodium ions, potassium ions, and water through urine.

Buyer Products:

  • Duramed Ziac (Bisoprolol Fumarate/Hydrochlorothiazide)
  
Calcium Channel Blocking Agents
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle and increasing the excretion of sodium ions, potassium ions, and water through urine.

Target Products:

  • Cardizem LA (Diltiazem Hydrochloride)
  
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by increasing the excretion of water and sodium, but not potassium in urine.

Buyer Products:

  • Amiloride Hydrochloride/Hydrochlorothiazide
  • Triamterene/Hydrochlorothiazide
  
Peripheral Vascular Disease
Free Fatty Acid Inhibitors/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat arterial obstruction outside of the heart by inhibiting the release of fatty acids from adipose tissue and blocking cholesterol synthesis by binding a key enzyme in the synthesis process.

Buyer Products:

  • Advicor (Niacin/Lovastatin)

Target Products:

  • Advicor (Niacin/Lovastatin)
Thromboembolism  
Anticoagulating Agents (Anticoagulants)  
Platelet Aggregation Inhibitors  
Phosphodiesterase Inhibitors
Therapeutics that treat the obstruction of a blood vessel by preventing platelets from clumping together.

Buyer Products:

  • Dipyridamole
  
Thrombin Inhibitors
Therapeutics that treat the obstruction of a blood vessel by preventing blood clots from forming.

Buyer Products:

  • Warfarin Sodium
  
Dermatology  
Acne  
Vulgaris  
Antibacterial Agents  
Macrolides
Therapeutics that treat acne vulgaris caused by bacterial infection by inhibiting RNA-dependent bacterial protein synthesis.

Buyer Products:

  • Erythromycin
  
Tetracyclines
Therapeutics that treat acne caused by bacterial infections by inhibiting protein synthesis and also causing alterations in cytoplasmic membranes.

Buyer Products:

  • Tetracycline Hydrochloride
  
Retinoids/Vitamin A Analogs
Therapeutics that treat acne by helping in cell differentiation as well as prevent cell proliferation.

Buyer Products:

  • Claravis (Isotretinoin)
  
Lesion/Scaling Disorders  
Chronic Urticaria  
Antihistamines
Therapeutics that treat allergic skin conditions by blocking the action of histamines.

Buyer Products:

  • Fexofenadine Hydrochloride (12 Hours Extended Release)
  • Fexofenadine Hydrochloride
  
Pruritus  
Antihistamines
Therapeutics that inhibit inflammation by blocking the action of histamines on tissues.

Buyer Products:

  • Hydroxyzine Pamoate
  
Psoriasis  
Dihydrofolate Reductase Inhibitors
Therapeutics that treat a slow growing, chronic inflammatory skin disorder characterized by dry, scaling patches by inhibiting an enzyme needed for the synthesis of DNA.

Buyer Products:

  • Trexall (Methotrexate)
  • Methotrexate Sodium
  
Digestive System
Gastrointestinal Tract Disorders  
Gastroesophageal Disorders  
Nausea/Vomiting  
Dopamine Receptor Blocking Agents
Therapeutics that treat or prevent nausea and vomiting by blocking the action of dopamine.

Buyer Products:

  • Prochlorperazine Maleate
  
Liver Disorders  
Cirrhosis  
Complications  
Edema  
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissue by increasing the excretion of sodium and water, but not potassium in urine.

Buyer Products:

  • Triamterene/Hydrochlorothiazide
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of digestive disorders in early stages of clinical research where human subject is involved.

Target Products:

  • Icatibant
  • KS 99-407
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of digestive disorders in very early stages of research where no human subject is involved.

Target Products:

  • KS 99-407
  
Endocrinology/Metabolism
Adrenal Gland Disorders  
Adrenocortical Insufficiency  
Synthetic Adrenocortical Steroids
Therapeutics that treat Adrenocortical Insufficiency by acting on the distal tubules of the kidney to enhance the reabsorption of sodium ions and to increase the urinary excretion of both potassium and hydrogen ions.

Buyer Products:

  • Fludrocortisone Acetate
  
Diabetes  
Induced Complications  
Central Diabetes Insipidus  
Antidiuretic Agents
Therapeutics that treat prevent the lose of water in the urine.

Buyer Products:

  • Desmopressin Acetate
  
Non-Insulin Dependent Diabetes Mellitus (NIDDM)/Type 2 Diabetes  
Biguanides
Therapeutics that treat abnormally high blood glucose levels by decreasing the production of glucose in the liver, decreasing intestinal absorption of glucose and increasing peripheral uptake and utilization of glucose.

Buyer Products:

  • Metformin Hydrochloride Extended-Release
  • Metformin Hydrochloride
  
Insulin Stimulating Agents (Sulfonylureas)
Therapeutics that treat non-insulin dependent diabetes by stimulating the secretion of insulin.

Buyer Products:

  • Acetohexamide
  
General Hormone Treatments  
Estrogens
Therapeutics that treat hormonal disorders by providing estrogen.

Buyer Products:

  • Duramed Enjuvia (Synthetic Conjugated Estrogens)
  • Estropipate
  • Duramed Cenestin (Synthetic Conjugated Estrogens, A)
  • Estradiol
  
Prednisolones
Therapeutics that treat inflammation by preventing the accumulation of inflammatory cells, like macrophages and leukocytes to the inflammation sites.

Buyer Products:

  • Methylprednisolone
  
Intermediary Metabolism Disorders
Gout  
Gouty Arthritis  
Urate Resorption Inhibitors
Therapeutics that treat gouty arthritis by preventing the active reabsorption of urate at the renal tubule thus increasing the excretion of urinary acid and lowering serum concentrations of urate.

Buyer Products:

  • Sulfinpyrazone
  
Hyperuricemia  
Urate Resorption Inhibitors
Therapeutics that inhibit the resorption of urate from the kidneys.

Buyer Products:

  • Sulfinpyrazone
  
Hypercholesterolemia
Free Fatty Acid Inhibitors
Therapeutics that treat the abnormally high concentrations of cholesterol by inhibiting the release of fatty acids from adipose tissue.

Buyer Products:

  • Niacin Extended-Release
  • Niaspan (Niacin)

Target Products:

  • Niaspan (Niacin)
  • Niaspan CF (Niacin)
Free Fatty Acid Inhibitors/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat elevated cholesterol by inhibiting the release of fatty acids from adipose tissue and blocking cholesterol synthesis by binding a key enzyme in the synthesis process.

Buyer Products:

  • Advicor (Niacin/Lovastatin)

Target Products:

  • Advicor (Niacin/Lovastatin)
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.

Buyer Products:

  • Pravastatin Sodium
  
Hyperlipidemia
Free Fatty Acid Inhibitors
Therapeutics that inhibit the release of fatty acids from adipose tissue.

Buyer Products:

  • Niacin Extended-Release
  • Niaspan (Niacin)

Target Products:

  • Niaspan (Niacin)
Free Fatty Acid Inhibitors/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat hyperlipidemia by inhibiting the release of free fatty acid from adipose tissues as well as blocking cholesterol synthesis by binding a key enzyme in the synthesis process.

Buyer Products:

  • Advicor (Niacin/Lovastatin)

Target Products:

  • Advicor (Niacin/Lovastatin)
  • Simcor (Niacin/Simvastatin)
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.

Buyer Products:

  • Pravastatin Sodium
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of endocrinology disorders in early stages of clinical research where human subject is involved.

Target Products:

  • KS 01-017
  • KI 02-212 (Inhaled Insulin)
  
Reproductive Disorders  
Amenorrhea  
Progestins
Female sex hormone necessary for the development of the female reproductive system.

Buyer Products:

  • Medroxyprogesterone
  • Duramed Aygestin (Norethindrone Acetate)
  
Menopause  
Estrogens
Therapeutics that are female sex hormones.

Buyer Products:

  • Duramed Cenestin (Synthetic Conjugated Estrogens, A)
  • Estradiol
  • Estropipate
  • Duramed Enjuvia (Synthetic Conjugated Estrogens)
  
Estrogens/Progestins
Therapeutics that are mixture of two female sex hormones that are important for the development of the female reproductive system.

Buyer Products:

  • Duramed Prefest (17-Estradiol/Norgestimate)
  • Nevis (Norethindrone Acetate/Ethinyl Estradiol)
  
Progestins
Therapeutics that are female sex hormones.

Buyer Products:

  • Medroxyprogesterone
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of endocrinology disorders in very early stages of research where no human subject is involved.

Target Products:

  • KS 01-017
  • KH01503
  • KH01501
  • KHO1502
  • KH01500
  • Simcor (Niacin/Simvastatin)
  
Hematology
Hemophilia  
Hemophilia A  
Antidiuretic Agents
Therapeutics that treat prevent the loss of water in the urine.

Buyer Products:

  • Desmopressin Acetate
  
Red Blood Cell (RBC) Disorders  
Anemia  
Folic Acid Derivatives
Therapeutics that treat conditions characterized by reduced delivery of oxygen to body tissues caused by folic acid deficiency.

Buyer Products:

  • Leucovorin
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of hematological disorders in very early stages of research where no human subject is involved.

Target Products:

  • KH01500
  • Simcor (Niacin/Simvastatin)
  • KI 04 208
  • KHO1502
  • KH01501
  • KH01503
  
Serum Factor Disorders
Hypercholesterolemia
Free Fatty Acid Inhibitors
Therapeutics that treat the abnormally high concentrations of cholesterol by inhibiting the release of fatty acids from adipose tissue.

Buyer Products:

  • Niaspan (Niacin)
  • Niacin Extended-Release

Target Products:

  • Niaspan CF (Niacin)
  • Niaspan (Niacin)
Free Fatty Acid Inhibitors/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat the abnormally high concentrations of cholesterol by inhibiting the release of fatty acids from adipose tissue and blocking cholesterol synthesis by binding a key enzyme in the synthesis process.

Buyer Products:

  • Advicor (Niacin/Lovastatin)

Target Products:

  • Advicor (Niacin/Lovastatin)
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.

Buyer Products:

  • Pravastatin Sodium
  
Hyperlipidemia
Free Fatty Acid Inhibitors
Therapeutics that inhibit the release of fatty acids from adipose tissue.

Buyer Products:

  • Niacin Extended-Release

Target Products:

  • Niaspan (Niacin)
Free Fatty Acid Inhibitors/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat hyperlipidemia by inhibiting the release of free fatty acid from adipose tissues as well as blocking cholesterol synthesis by binding a key enzyme in the synthesis process.

Buyer Products:

  • Advicor (Niacin/Lovastatin)

Target Products:

  • Advicor (Niacin/Lovastatin)
  • Simcor (Niacin/Simvastatin)
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.

Buyer Products:

  • Pravastatin Sodium
  
Hyperuricemia  
Urate Resorption Inhibitors
Therapeutics that prevents the resorption of urate within the kidneys.

Buyer Products:

  • Sulfinpyrazone
  
Hypokalemia  
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat hypokalemia by promoting excretion while inhibiting the removal of potassium.

Buyer Products:

  • Triamterene/Hydrochlorothiazide
  
Thrombocyte (Platelet) Disorders  
Thrombocythemia  
Megakaryocyte Maturation Inhibitors
Therapeutics that prevents the maturation of platelet producing cells.

Buyer Products:

  • Anagrelide Hydrochloride
  
Immunology
Autoimmune Disorders  
Arthritis  
Rheumatoid Arthritis (RA)  
Disease Modifying Anti-Rheumatic Drugs (DMARD)  
Dihydrofolate Reductase Inhibitors
Therapeutics that alter or delay the rate of chronic joint inflammation by blocking the action of the dihydrofolate enzyme.

Buyer Products:

  • Methotrexate Sodium
  • Trexall (Methotrexate)
  
Pyrimidine Synthesis Inhibitors
Therapeutics that alter or delay the rate of chronic joint inflammation by blocking the overproduction of immune cells.

Buyer Products:

  • Leflunomide
  
Psoriasis  
Dihydrofolate Reductase Inhibitors
Therapeutics that treat a chronic autoimmune disease characterized by thickened skin with silver scales by blocking the action of the dihydrofolate enzyme.

Buyer Products:

  • Trexall (Methotrexate)
  • Methotrexate Sodium
  
Immune Deficiency Disorders
Hereditary Angioedema
Bradykinin B2 Receptor Antagonists
Therapeutics that treat swelling under the skin caused by the absence of an essential immune regulator by inhibiting the release of bradykinin, a peptide hormone which is released during trauma.

Target Products:

  • Icatibant
  
Gonadotropin Inhibitors
Therapeutics that treat swelling under the skin caused by the absence of an essential immune regulator by increasing levels of C4 complement component.

Buyer Products:

  • Danazol
  
Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS)  
Nucleoside Reverse Transcriptase Inhibitors (NRTI)
Therapeutics that help manage HIV by inhibiting the action of reverse transcriptase, an enzyme necessary for the DNA synthesis on a RNA template.

Buyer Products:

  • Didanosine Delayed Release
  
Infectious Diseases  
Bacterial  
Antibacterial Agents  
Broad Spectrum  
Antibiotics  
Macrolides
Therapeutics that treat a wide variety of infections by inhibiting RNA-dependent bacterial protein synthesis.

Buyer Products:

  • Erythromycin
  
Quinolones/Fluoroquinolones
Therapeutics that treat a wide variety of infections by promoting breakage of bacterial DNA strands.

Buyer Products:

  • Ciprofloxacin
  
Tetracyclines
Therapeutics that treat a wide variety of infections by inhibiting protein synthesis and also causing alterations in cytoplasmic membranes.

Buyer Products:

  • Tetracycline Hydrochloride
  • Demeclocycline Hydrochloride
  
Narrow Spectrum  
Otolaryngology (Ear/Nose/Throat)  
Otitis Media  
Macrolides/Sulfonamides
Therapeutics that treat infection and inflammation of the middle ear space and ear drum by inhibiting RNA-dependent bacterial protein synthesis and by inhibiting folic acid synthesis.

Buyer Products:

  • Erythromycin Ethylsuccinate/Sulfisoxazole
  
Respiratory System  
Pneumonia  
Quinolones/Fluoroquinolones
Therapeutics that treat inflammation of the lungs caused by bacterial infection by bacterial infection by promoting breakage of bacterial DNA strands.

Buyer Products:

  • Ciprofloxacin
  
Respiratory Tract Infections  
Quinolones/Fluoroquinolones
Therapeutics that treat bacterial infections of the air passage involved in breathing, including the trachea, lungs and bronchi by promoting breakage of bacterial DNA strands.

Buyer Products:

  • Ciprofloxacin
  
Tuberculosis  
Antitubercular Agents
Therapeutics that treat a bacterial infection of the lung by inhibiting bacterial and mycobacterial RNA synthesis.

Buyer Products:

  • Ethambutol Hydrochloride
  • Isoniazid
  
Systemic  
Leprosy  
Erythema Nodosum Leprosum (ENL)  
Immunomodulatory Agents
Therapeutics that treat a bacterial infection characterized by the formation of tender, red nodules on the front of the legs by stimulating the immune system.

Buyer Products:

  • Thalidomide
  
Urology  
Prostatitis  
Quinolones/Fluoroquinolones
Therapeutics that treat a wide variety of infections by promoting breakage of bacterial DNA strands.

Buyer Products:

  • Ciprofloxacin
  
Urinary Tract Infections (UTI)  
Antibacterial Agents (Antibiotics)  
Quinolones/Fluoroquinolones
Therapeutics that treat bacterial infections of the urethra, urinary bladder, ureters, and kidneys by promoting breakage of bacterial DNA strands.

Buyer Products:

  • Ciprofloxacin
  
Mycological (Fungal)  
Antifungal Agents  
Broad Spectrum  
Azoles  
Triazoles
Therapeutics that treat fungal infections by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.

Buyer Products:

  • Fluconazole
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in early stages of clinical research where human subject is involved.

Buyer Products:

  • Adenovirus Vaccine
  
Protozoal  
Antiprotozoal Agents  
Narrow Spectrum  
Malaria  
Aminoquinolines
Therapeutics that treat parasitic infections caused by Plasmodia in red blood cells by inhibiting parasite growth.

Buyer Products:

  • Mefloquine Hydrochloride
  
Viral  
RNA Viruses  
Retrovirus  
Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS)  
Nucleoside Reverse Transcriptase Inhibitors (NRTI)
Therapeutics that help manage HIV by inhibiting the action of reverse transcriptase, an enzyme necessary for the DNA synthesis on a RNA template.

Buyer Products:

  • Didanosine Delayed Release
  
Musculoskeletal System  
Skeletal Disorders  
Bone Disorders  
Osteoporosis  
Hormonal Treatments  
Estrogens
Therapeutics that treat osteoporosis by providing female hormones which results in a decrease in the rate of bone loss due to osteoclasts.

Buyer Products:

  • Estropipate
  • Estradiol
  
Estrogens/Progestins
Therapeutics that treat osteoporosis by providing female hormones which results in a decrease in the rate of bone loss due to osteoclasts.

Buyer Products:

  • Duramed Prefest (17-Estradiol/Norgestimate)
  • Nevis (Norethindrone Acetate/Ethinyl Estradiol)
  
Joint Disorders  
Gouty Arthritis  
Urate Resorption Inhibitors
Therapeutics that treat gouty arthritis by preventing the active reabsorption of urate at the renal tubule thus increasing the excretion of urinary acid and lowering serum concentrations of urate.

Buyer Products:

  • Sulfinpyrazone
  
Rheumatoid Arthritis (RA)  
Disease Modifying Anti-Rheumatic Drugs (DMARD)  
Dihydrofolate Reductase Inhibitors
Therapeutics that alter or delay the rate of chronic joint inflammation by blocking the action of the dihydrofolate enzyme.

Buyer Products:

  • Trexall (Methotrexate)
  • Methotrexate Sodium
  
Pyrimidine Synthesis Inhibitors
Therapeutics that alter or delay the rate of chronic joint inflammation by blocking the overproduction of immune cells.

Buyer Products:

  • Leflunomide
  
Neurology  
Neurological Disorders  
Alzheimer`s Disease  
Acetylcholinesterase Inhibitors/Nicotinic Receptor Modulators
Therapeutics that treat Alzheimer's Disease by preventing the breakdown of a the neurotransmitter, acetylcholine, and by modulating the receptor that binds nicotine.

Buyer Products:

  • Galantamine Hydrobromide
  
Epilepsy  
Partial Seizures  
Complex  
Adjunctive Therapy  
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat complex partial seizures by preventing the uptake of gamma-aminobutyric acid as well as blocking the sodium channels which in turn block the conductance of electrical impulses through the brain.

Buyer Products:

  • Zonisamide
  • Topiramate
  
Monotherapy  
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat complex partial seizures by preventing the uptake of gamma-aminobutyric acid as well as blocking the sodium channels which in turn block the conductance of electrical impulses through the brain.

Buyer Products:

  • Topiramate
  
Simple  
Adjunctive Therapy  
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat simple partial seizure by both preventing the uptake of gamma-aminobutyric acid which prevents nerve activation as well as blocking the sodium channels which in turn block the conductance of neural impulses.

Buyer Products:

  • Zonisamide
  • Topiramate
  
Monotherapy  
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat simple partial seizure by both preventing the uptake of gamma-aminobutyric acid which prevents nerve activation as well as blocking the sodium channels which in turn block the conductance of neural impulses.

Buyer Products:

  • Topiramate
  
Primary Generalized Seizures  
Absence (Petit Mal)  
Adjunctive Therapy  
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Petit Mal Seizures by preventing the uptake of molecules that prevents nerve activation.

Buyer Products:

  • Clonazepam ODT
  
Monotherapy  
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Petit Mal Seizures by preventing the uptake of molecules that prevents nerve activation.

Buyer Products:

  • Clonazepam ODT
  
Akinetic Pattern  
Adjunctive Therapy  
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Akinetic Pattern Seizures by preventing the uptake of molecules that prevents nerve activation.

Buyer Products:

  • Clonazepam ODT
  
Monotherapy  
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Akinetic Pattern Seizures by preventing the uptake of molecules that prevents nerve activation.

Buyer Products:

  • Clonazepam ODT
  
Myoclonic  
Adjunctive Therapy  
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Myoclonic Seizures by inhibiting the uptake of molecules that prevent nerve activation.

Buyer Products:

  • Clonazepam ODT
  
Monotherapy  
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Myoclonic Seizures by inhibiting the uptake of molecules that prevents nerve activation.

Buyer Products:

  • Clonazepam ODT
  
Tonic-Clonic (Grand Mal)  
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat simple partial seizure by both preventing the uptake of gamma-aminobutyric acid which prevents nerve activation as well as blocking the sodium channels which in turn block the conductance of neural impulses.

Buyer Products:

  • Topiramate
  
Headaches  
Tension Type  
Analgesics/Sedatives/Vasoconstrictive Agents
Therapeutics that treat tension type headaches by inhibiting the action of prostaglandins, constricting blood vessels in the brain thus reducing the pulsing action of blood in the cerebral arteries, and exerting a mild sedative effect.

Buyer Products:

  • Duradrin (Isometheptene/Dichloralphenazone/Acetaminophen)
  • Isometheptene/Dichloralphenazone/Acetaminophen
  
Vascular (Migraine)  
Acute Treatments  
Analgesics/Sedatives/Vasoconstrictive Agents
Therapeutics that treat migraine by inhibiting the action of prostaglandins, constricting blood vessels in the brain thus reducing the pulsing action of blood in the cerebral arteries, and exerting a mild sedative effect.

Buyer Products:

  • Isometheptene/Dichloralphenazone/Acetaminophen
  • Duradrin (Isometheptene/Dichloralphenazone/Acetaminophen)
  
Neuromuscular Disorders  
Myasthenia Gravis (MG)  
Cholinesterase Inhibitors
Therapeutics that treat Myasthenia Gravis by maintaining the transmission of nerve impulses by inhibiting the enzyme that breaks down acetylcholine.

Buyer Products:

  • Pyridostigmine Bromide
  
Psychiatric Disorders  
Anxiety  
Generalized Anxiety Disorder (GAD)  
Antihistamines
Therapeutics that treat anxiety by blocking the action of histamines.

Buyer Products:

  • Hydroxyzine Pamoate
  
Dopamine Receptor Blocking Agents
Therapeutics that treat anxiety by blocking dopamine receptors.

Buyer Products:

  • Prochlorperazine Maleate
  
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat anxiety by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid.

Buyer Products:

  • Diazepam
  • Chlordiazepoxide Hydrochloride
  • Alprazolam Extended Release
  
Obsessive Compulsive Disorder (OCD)  
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat Anxiety by selectively preventing the removal of serotonin.

Buyer Products:

  • Fluvoxamine Maleate
  • Fluoxetine Hydrochloride
  
Panic Disorder  
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat panic disorder by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid.

Buyer Products:

  • Alprazolam Extended Release
  • Clonazepam ODT
  
Childhood/Adolescent Disorders  
Attention Deficit Disorder (ADD)/Attention Deficit Hyperactivity Disorder (ADHD)  
Sympathomimetic Agents
Therapeutic members of the amphetamine group of sympathomimetic amines that treat the disorder involving hyperactivity in children due to an abnormally short attention span.

Buyer Products:

  • Dextroamphetamine Sulfate Extended Release
  • Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate And Amphetamine Sulfate Tablets
  
Enuresis (Bedwetting)  
Antidiuretic Agents
Therapeutics that treat enuresis by suppressing the passing of urine.

Buyer Products:

  • Desmopressin Acetate
  
Eating Disorders  
Bulimia  
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat eating disorders by selectively preventing the removal of serotonin.

Buyer Products:

  • Fluoxetine Hydrochloride
  
Mood Disorders  
Bipolar Disorders (Manic Depressive Disorders)  
Lithium-Based Agents
Therapeutics that treat bipolar disorders by decreasing the concentrations of neurotransmitters.

Buyer Products:

  • Lithium Carbonate Extended Release
  
Monoaminergic Antagonists
Therapeutics that treat bipolar disorder by blocking the serotonin and dopamine receptors.

Buyer Products:

  • Risperidone
  • Olanzapine
  
Depression  
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat depression by selectively preventing the removal of serotonin.

Buyer Products:

  • Trazodone Hydrochloride
  • Fluoxetine Hydrochloride
  
Tetracyclic Compounds
Therapeutics that treat depression by increasing the synaptic concentrations of norepinephrine.

Buyer Products:

  • Mirtazapine
  
Schizophrenia  
Dopamine Receptor Blocking Agents
Therapeutics that treat schizophrenia by blocking the dopamine receptors.

Buyer Products:

  • Prochlorperazine Maleate
  
Monoaminergic Antagonists
Therapeutics that treat schizophrenia by blocking the serotonin and dopamine receptors.

Buyer Products:

  • Olanzapine
  • Risperidone
  
Sleep Disorders  
Insomnia  
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat insomnia by enhancing the inhibitory action of gamma-aminobutyric acid.

Buyer Products:

  • Diazepam
  
Narcolepsy  
Alpha Adrenergic Receptor Agonists
Therapeutics that treat narcolepsy by stimulating the adrenergic receptors, which causes nervous system stimulation.

Buyer Products:

  • Modafinil
  
Sympathomimetic Agents
Therapeutic members of the amphetamine group of sympathomimetic amines that treat the disorder involving hronic and sudden daytime sleepiness.

Buyer Products:

  • Dextroamphetamine Sulfate Extended Release
  
Obstetrics/Gynecology
Child Birth/Pregnancy  
Prevention (Contraception)  
Contraceptives (Birth Control)  
Estrogens
Therapeutics that prevent conception by decreasing the secretion of gonadotropin-releasing hormone in the hypothalamus, resulting in an anti-ovulatory effect.

Buyer Products:

  • Kelnor (Ethynodiol Diacetate/Ethinyl Estradiol)
  
Estrogens/Progestins
Therapeutics that prevent conception by decreasing the secretion of gonadotropin-releasing hormone in the hypothalamus, resulting in an anti-ovulatory effect.

Buyer Products:

  • Velivet (Desogestrel/Ethinyl Estradiol)
  • Portia (Levonorgestrel/Ethinyl Estradiol)
  • Enpresse (Levonorgestrel/Ethinyl Estradiol)
  • Kariva (Desogestrel/Ethinyl Estradiol)
  • Lessina (Levonorgestrel/Ethinyl Estradiol)
  • Nortrel (Ethinyl Estradiol/Norethindrone) 7/7/7
  • Duramed Seasonale (Levonorgestrel/Ethinyl Estradiol)
  • Sprintec/Tri-Sprintec (Norgestimate/Ethinyl Estradiol)
  • Aviane 28 (Levonorgestrel/Ethinyl Estradiol)
  • Cryselle (Norgestrel/Ethinyl Estradiol)
  • Duramed Nordette Tablets (Levonorgestrel/Ethinyl Estradiol)
  • Seasonique Extended Release (Levonorgestrel/Ethinyl Estradiol)
  • Loestrin Fe (Norethindrone Acetate, Ethinyl Estradiol, Ferrous Fumarate)
  • Junel (Norethindrone Acetate, Ethinyl Estradiol, Ferrous Fumarate)
  • Drospirenone/Ethinyl Estradiol
  • Lo Seasonale (Levonorgestrel/Ethinyl Estradiol)
  • Apri (Desogestrel/Ethinyl Estradiol)
  • Mircette (Desogestrel Ethinyl Estradiol)
  • Aranelle (Norethindrone/Ethinyl Estradiol)
  
Progestins
Contraceptive Therapeutics that are female sex hormone necessary for the development of the female reproductive system

Buyer Products:

  • Plan B OTC (Levonorgestrel)
  • Errin (Norethindrone)
  • Norethindrone Acetate
  • Camila (Norethindrone)
  • Plan B Prescription (Levonorgestrel)
  
Female Genital Disorders  
Endometriosis  
Gonadotropin Inhibitors
Therapeutics that treat endometriosis by preventing the release of the pituitary gland hormone, gonadotropin.

Buyer Products:

  • Danazol
  
Ovarian  
Hypogonadism  
Hormonal Treatments  
Estrogens
These are female sex hormones.

Buyer Products:

  • Estradiol
  • Estropipate
  
Vulvovaginal  
Atrophy  
Hormonal Treatments  
Estrogens
Therapeutics that treat disorders characterized by thinning of the vaginal walls with the female sex hormone estrogen.

Buyer Products:

  • Estradiol
  • Duramed Cenestin (Synthetic Conjugated Estrogens, A)
  • Estropipate
  • Bijuva Cream (Synthetic Conjugated Estrogens, A)
  
Estrogens/Progestins
Therapeutics that treat disorders characterized by thinning of the vaginal walls with a combination of the female sex hormones estrogen and progestin.

Buyer Products:

  • Duramed Prefest (17-Estradiol/Norgestimate)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of female reproductive disorders in very early stages of research where no human subject is involved.

Target Products:

  • KI03218
  
Oncology  
Breast Cancer  
Localized  
Antimetabolite Agents  
Dihydrofolate Reductase Inhibitors
Therapeutics that treat and manage breast cancers by inhibiting an enzyme needed for the synthesis of DNA.

Buyer Products:

  • Methotrexate Sodium
  • Trexall (Methotrexate)
  
Estrogen Receptor Blocking Agents
Therapeutics that treat and manage breast cancers by blocking the uptake of estrogen which has been implicated in causing breast cancer.

Buyer Products:

  • Tamoxifen Citrate
  
Progestins
Therapeutics that treat and manage breast cancers by providing progestins which in turn results in decreased estrogen levels.

Buyer Products:

  • Megestrol Acetate
  
Metastatic  
Estrogen Receptor Blocking Agents
Therapeutics that treat and manage breast cancer by blocking the uptake of estrogen which has been implicated in causing breast cancer.

Buyer Products:

  • Tamoxifen Citrate
  
Dermatology  
Malignant Melanoma  
Ribonucleotide Reductase Inhibitors
Therapeutics that treat and manage cancers of pigment cells in the epidermis and dermis by interfering with DNA synthesis.

Buyer Products:

  • Hydroxyurea
  
Digestive System  
Colon Cancer/Colorectal Cancer  
Palliative Agents  
Folic Acid Derivatives
Therapeutics that treat colorectal cancers by helping to reduce toxicity by allowing DNA/RNA/Protein synthesis to occur even when the pathway has been blocked by folic acid antagonists.

Buyer Products:

  • Leucovorin
  
Head/Neck Cancer  
Localized  
Antimetabolite Agents  
Dihydrofolate Reductase Inhibitors
Therapeutics that treat and manage primary tumors of the head and neck by inhibiting the production of DNA.

Buyer Products:

  • Trexall (Methotrexate)
  • Methotrexate Sodium
  
Ribonucleotide Reductase Inhibitors
Therapeutics that treat and manage primary tumors of the head and neck by interfering with DNA synthesis.

Buyer Products:

  • Hydroxyurea
  
Hematology  
Leukemia  
Lymphoid  
Acute  
Lymphocytic  
Antimetabolite Agents  
Dihydrofolate Reductase Inhibitors
Therapeutics that treat and manage rapidly progressing cancers of lymphocytic cells by inhibiting an enzyme needed for the synthesis of DNA.

Buyer Products:

  • Trexall (Methotrexate)
  • Methotrexate Sodium
  
Meningeal  
Antimetabolite Agents  
Dihydrofolate Reductase Inhibitors
Therapeutics that treat and manage neoplasm's of immature immune cells that have spread to the brain by inhibiting an enzyme needed for the synthesis of DNA.

Buyer Products:

  • Trexall (Methotrexate)
  • Methotrexate Sodium
  
Myeloid  
Chronic  
Myelogenous (CML)  
Ribonucleotide Reductase Inhibitors
Therapeutics that treat and manage slowly progressing cancers of myelogenous cells by interfering with DNA synthesis.

Buyer Products:

  • Hydroxyurea
  
Lymphoma  
Non-Hodgkin`s Lymphoma (NHL)  
Antimetabolite Agents  
Dihydrofolate Reductase Inhibitors
Therapeutics that treat and manage lymphomas of B-cells and T-cells by inhibiting the production of DNA.

Buyer Products:

  • Trexall (Methotrexate)
  • Methotrexate Sodium
  
Multiple Myeloma (MM)  
Immunomodulatory Agents
Therapeutics that treat multiple myeloma by stimulating the immune system.

Buyer Products:

  • Thalidomide
  
Musculoskeletal System  
Bone Cancer  
Osteosarcoma  
Palliative Agents  
Folic Acid Derivatives
Therapeutics that are meant to reduce the toxicity of treating malignant tumors of the bone by allowing DNA/RNA/Protein synthesis to occur even when the pathway has been blocked by folic acid antagonists.

Buyer Products:

  • Leucovorin
  
Urology  
Endometrial Cancer  
Localized  
Progestins
Therapeutics that treat and manage cancer of the endometrial cells lining the uterus by providing a female sex hormone necessary for the development of the female reproductive system.

Buyer Products:

  • Megestrol Acetate
  
Kidney Cancer (Renal Cell Carcinoma)  
Metastatic  
Hormonal Treatments  
Progestins
Therapeutics that treat and manage renal cancers that have spread beyond their original tumor site by supplying a female sex hormone necessary for the development of the female reproductive system.

Buyer Products:

  • Megestrol Acetate
  
Ovarian Cancer  
Adenocarcinoma  
Ribonucleotide Reductase Inhibitors
Therapeutics that treat and manage cancer of cells lining the ovary by interfering with DNA synthesis.

Buyer Products:

  • Hydroxyurea
  
Prostate Cancer  
Localized  
Androgen Receptor Blockers
Therapeutics that treat prostate cancer by blocking androgen receptors. This limits the action of male hormones which have been implicated as a causative agent in prostate cancer.

Buyer Products:

  • CyPat (Cyproterone)
  
Metastatic  
Androgen Receptor Blockers
Therapeutics that treat and manage prostate cancers that have spread beyond their original tumor site by binding to the androgen receptors in target tissue thus inhibiting the action of androgens.

Buyer Products:

  • Flutamide
  
Ophthalmology  
Degenerative Disorders  
Glaucoma  
Carbonic Anhydrase Inhibitors
Therapeutics that decrease the formation of the fluid of the eye.

Buyer Products:

  • Duramed Diamox (Acetazolamide)
  
Pain Management  
Anesthesia  
General (Systemic)  
Adjunctive  
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that result in anesthesia by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid.

Buyer Products:

  • Diazepam
  
Narcotics  
Analgesics/Opioids
Therapeutics that treat pain by binding to certain nervous system receptors which alters the both the perception of pain as well as the emotional response to pain.

Buyer Products:

  • Oxycodone/Acetaminophen
  • Acetaminophen/Codeine
  
Opioids
Therapeutics that treat pain by binding to certain nervous system receptors which alter both the perception of pain as well as the emotional response to pain.

Buyer Products:

  • Meperidine Hydrochloride
  • Oral Transmucosal Fentanyl Citrate [C-II]
  
Non-Narcotics  
Skeletal Muscle Relaxing Agents
Therapeutics that treat pain by depressing specific synaptic reflexes preferentially.

Buyer Products:

  • Chlorzoxazone
  
Respiratory System
Lower Respiratory Tract Disorders (Lung Disorders)  
Asthma  
Prophylactic Treatments  
Beta Adrenergic Receptor Agonists/Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat asthma by reducing inflammation in the lungs with steroids and that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine.

Target Products:

  • Flutiform (Formoterol/Fluticasone)
  
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat asthma by reducing inflammation in the lung passages with steroids.

Target Products:

  • Azmacort HFA(EDC)
  • Azmacort Inhalation Aerosol
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of respiratory disorders in early stages of clinical research where human subject is involved.

Target Products:

  • Icatibant
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of respiratory disorders in very early stages of research where no human subject is involved.

Target Products:

  • KI03219
  • KI04204
  
Upper Respiratory Tract Disorders  
Coughs/Colds  
Antihistamines
Therapeutics that inhibit the inflammation by blocking the action of histamines on tissues.

Buyer Products:

  • Fexofenadine Hydrochloride (12 Hours Extended Release)
  • Diphenhydramine Hydrochloride
  
Decongestants/Expectorants/Opioids
Therapeutics that treat coughs and colds by reducing mucous build up, suppressing coughs and help in ejection of mucous.

Buyer Products:

  • MedTuss HD Elixir C-III
  
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress the inflammation in the upper respiratory tract with steroidal compounds.

Buyer Products:

  • Triamcinolone Acetonide Nasal Spray
  
Surgery  
Cardiovascular System  
Thrombosis  
Thrombin Inhibitors
Therapeutics that thin the blood of a blocked blood vessel during surgery by blocking an enzyme involved in the clotting process.

Buyer Products:

  • Warfarin Sodium
  
Musculoskeletal System  
Deep Vein Thrombosis (DVT)  
Anticoagulating Agents (Anticoagulants)  
Thrombin Inhibitors
Therapeutics that treat vascular obstructions due to platelets and cell matter by blocking an enzyme involved in the clotting process.

Buyer Products:

  • Warfarin Sodium
  
Toxicology  
Substance Abuse  
Withdrawal  
Alcohol  
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat alcohol withdrawal by increasing the effect of GABA at the relevant neuroreceptors.

Buyer Products:

  • Diazepam
  • Chlordiazepoxide Hydrochloride
  
Opioid Antagonists
Therapeutics that treat alcohol dependence by blocking the effect of opioids.

Buyer Products:

  • Duramed ReVia (Naltrexone Hydrochloride)
  • Naltrexone Hydrochloride
  
Narcotics  
Opioid Antagonists
Therapeutics that treat narcotic addiction by blocking the effect of opioids.

Buyer Products:

  • Duramed ReVia (Naltrexone Hydrochloride)
  • Naltrexone Hydrochloride
  
Urology  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of urological disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • Oxybutynin TVR
  
Urological Disorders  
Kidney (Renal)  
Chronic Renal Failure (CRF)  
Complications  
Edema  
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissue by increasing the excretion of sodium and water, but not potassium in urine.

Buyer Products:

  • Triamterene/Hydrochlorothiazide
  
Weight Management
Anorexia (Appetite Loss)  
Progestins
Therapeutics that treat weight loss and other conditions arising from the uncontrolled loss of appetite by administration of hormone progestins.

Buyer Products:

  • Megestrol Acetate
  
Cachexia  
Anabolic Testosterone Analogs
Therapeutics containing a class of compounds that boost the body's metabolism and help in gaining weight.

Buyer Products:

  • Oxandrolone
  
Progestins
Therapeutics that treat cachexia by providing female hormones.

Buyer Products:

  • Megestrol Acetate
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of weight disorders in early stages of clinical research where human subject is involved.

Target Products:

  • KD01026
  
Wound Management  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of wounds in very early stages of research where no human subject is involved.

Target Products:

  • Icatibant
  
Medical Devices
Drug Delivery  
Pulmonary Delivery  
Aerosol Therapy  
Metered Dose  
Liquid  
Breath Actuated (BAI)
Inhalation devices which are activated by the patients' inspiration

Target Products:

  • Breath-Actuated Inhaler (BAI)
  
General Surgery  
Invasive  
Transplantation  
Organ Preservation
Devices used to preserve organs prior to transplantation.

Buyer Products:

  • ViaSpan (Belzer UW)
  
Obstetrics/Gynecology  
Treatment  
Procedure Specific  
Contraception  
Intrauterine Devices (IUD)
IUDs, or Intrauterine devices, are a form of birth control used by women.

Buyer Products:

  • ParaGard T 380A
  
Outsourced Services  
Drug Delivery Technology  
Oral Delivery  
Polymer Coated
Drug Delivery Technologies used to deliver drugs in a polymer based matrix to hold/enclose the drug.

Target Products:

  • Solid-Dose Drug Delivery System
  

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Relationship Details

Key Competitors

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Overlap
  Novartis AG (ADR) n/a 137,633.808 20.06 18.92 3.80 3.74 3.57
Bristol Myers Squibb Co. n/a 50,367.902 22.71 24.61 2.69 2.82 10.43
Sciele Pharma Inc. n/a 814.257 18.26 19.77 2.90 2.85 12.82
DepoMed, Inc. n/a 134.439 n/a -3.76 17.51 11.12 n/a
Buyer
  Johnson & Johnson n/a 192,198.230 17.37 17.71 3.68 3.60 7.06
Roche Holding Ltd. (ADR) n/a 154,398.687 34.26 24.41 5.58 n/a 8.47
Novartis AG (ADR) n/a 137,633.808 20.06 18.92 3.80 3.74 3.57
Target
  Pfizer Inc. n/a 184,875.794 14.65 12.47 3.83 3.83 7.92
GlaxoSmithKline plc (ADR) n/a 149,540.389 14.29 14.90 3.29 3.50 14.48
Novartis AG (ADR) n/a 137,633.808 20.06 18.92 3.80 3.74 3.57
Merck & Co., Inc. n/a 95,524.127 18.81 17.37 4.27 4.31 5.44
AstraZeneca plc (ADR) n/a 86,846.087 14.88 14.54 3.39 3.35 8.71
Abbott Laboratories n/a 74,394.862 23.47 19.16 3.34 3.29 29.70
Bristol Myers Squibb Co. n/a 50,367.902 22.71 24.61 2.69 2.82 10.43
Schering-Plough Corporation n/a 35,003.503 35.75 28.78 3.41 3.37 4.54
Forest Laboratories, Inc. n/a 16,311.277 22.38 19.07 5.13 4.89 6.18
Nektar Therapeutics n/a 1,488.072 n/a -12.90 8.24 7.24 9.11
MannKind Corporation n/a 884.290 n/a -3.91 8,890.00 109.30 14.27
Sciele Pharma Inc. n/a 814.257 18.26 19.77 2.90 2.85 12.82
DepoMed, Inc. n/a 134.439 n/a -3.76 17.51 11.12 n/a
Medicure Inc. (USA) n/a 129.688 n/a n/a 158.82 n/a 15.15
IVAX Diagnostics, Inc. n/a 35.668 n/a n/a 1.84 n/a 1.72
Valentis, Inc. n/a 5.980 n/a n/a 12.45 n/a 7.63
Daiichi Sankyo Company, Limited n/a n/a n/a n/a n/a n/a n/a
Reliant Pharmaceuticals, LLC n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Dependent Suppliers

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  Mack-Cali Realty Corp. n/a 3,261.704 36.38 14.19 4.63 4.67 2.19
Common Sense Ltd. n/a n/a n/a n/a n/a n/a n/a
Target
  Barr Pharmaceuticals, Inc. n/a 5,484.312 17.92 16.27 4.10 3.47 4.41
Biovail Corporation (USA) n/a 3,276.926 15.73 8.21 3.12 3.20 7.15
Inyx, Inc. n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Key Customers

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Overlap
  Government - United States n/a n/a n/a n/a n/a n/a n/a
Buyer
  McKesson Corporation 27.00% 15,147.693 18.34 18.80 0.17 0.16 3.72
Cardinal Health, Inc. 15.00% 26,305.528 25.23 19.08 0.32 0.30 7.81
AmerisourceBergen Corp. 11.00% 8,918.669 19.07 18.60 0.15 0.14 5.74
Walgreen Company 10.00% 44,624.646 25.49 22.41 0.94 0.83 4.41
KOS Pharmaceuticals, Inc. n/a 3,715.206 54.14 42.16 4.37 4.27 6.42
Warner Chilcott Ltd. n/a 3,402.568 n/a 24.42 4.96 4.63 n/a
Government - United States n/a n/a n/a n/a n/a n/a n/a
Target
  Government - United States n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Key Partners

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  Teva Pharmaceutical Industries Ltd (ADR) n/a 24,468.181 62.58 13.76 3.25 2.90 33.99
Akzo Nobel N.V. (ADR) n/a 17,297.201 10.85 15.90 0.98 0.89 3.96
Shire plc (ADR) n/a 10,523.837 37.77 36.32 5.96 5.95 12.24
Cephalon, Inc. n/a 4,402.930 26.24 16.58 2.72 2.55 n/a
King Pharmaceuticals, Inc. n/a 3,957.934 25.14 9.72 2.08 2.06 3.30
KOS Pharmaceuticals, Inc. n/a 3,715.206 54.14 42.16 4.37 4.27 6.42
Warner Chilcott Ltd. n/a 3,402.568 n/a 24.42 4.96 4.63 n/a
Savient Pharmaceuticals, Inc. n/a 609.525 7.82 -579.50 9.73 8.63 3.33
Paladin Labs Inc. n/a 167.035 33.84 n/a 4.29 n/a 2.98
PLIVA d.d. n/a n/a n/a n/a n/a n/a n/a
Common Sense Ltd. n/a n/a n/a n/a n/a n/a n/a
Target
  Barr Pharmaceuticals, Inc. n/a 5,484.312 17.92 16.27 4.10 3.47 4.41
Biovail Corporation (USA) n/a 3,276.926 15.73 8.21 3.12 3.20 7.15
SkyePharma PLC (ADR) n/a 320.877 n/a n/a 3.38 n/a n/a
University of Southern California n/a n/a n/a n/a n/a n/a n/a
Strix Systems, Inc n/a n/a n/a n/a n/a n/a n/a
Boston University n/a n/a n/a n/a n/a n/a n/a
Arisaph Pharmaceuticals, Inc. n/a n/a n/a n/a n/a n/a n/a
Merck KGaA n/a n/a n/a n/a n/a n/a n/a
Tufts University n/a n/a n/a n/a n/a n/a n/a
Oryx Pharmaceuticals Inc. n/a n/a n/a n/a n/a n/a n/a
Jerini AG n/a n/a n/a n/a n/a n/a n/a
Inyx, Inc. n/a n/a n/a n/a n/a n/a n/a
University of Pennsylvania n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Financials

  Buyer Target Combined Entity
Income Statement
Operating Items
Revenue 1,202.4 849.3 2,051.7
Other Revenue 134.0 0.0 134.0
Total Revenue 1,336.4 849.3 2,185.7
Cost of Revenue 353.7 102.8 456.5
SG&A Expense 363.7 478.5 842.2
Depreciation & Amortization 0.0 0.0 0.0
Research & Development 145.1 170.6 315.6
Interest Expense 0.0 0.0 0.0
Other Operating Expense 0.0 0.0 0.0
Total Expenses 862.5 751.8 1,614.3
Operating Income 473.9 97.5 571.4
Non Operating Items
Interest Expense (Inc.), Net Non-Oprtng 20.6 18.5 39.1
Other, Net -25.2 -0.2 -25.5
Income Before Taxes 469.2 115.8 585.0
Income Taxes 163.2 47.2 210.4
Income After Taxes 306.0 68.6 374.6
Net Income - Excl. Xord. Items 306.0 68.6 374.6
Net Income - Incl. Xord. Items 306.0 68.6 374.6
Income Avail. to Common 306.0 68.6 374.6
Share Items
Basic Avg. Shares Outstanding 106.3 47.4 153.7
Basic EPS - Excl. Xord. Items 2.88 1.45 2.44
Basic EPS - Incl. Xord. Items 2.88 1.45 2.44
Full Dilution Adjustment 0.0 0.3 0.3
Fully Diluted Shares Outstanding 108.1 50.3 158.4
F.D. EPS - Excl. Xord. Items 2.83 1.36 2.37
F.D. EPS - Incl. Xord. Items 2.83 1.36 2.37
Balance Sheet
Assets
Cash and Equivalents 273.3 542.5 815.7
ST Investments 480.2 1.2 481.3
Accounts Receivable 212.9 123.8 336.7
Inventory 150.7 24.8 175.5
Prepayments and Advances 36.0 20.6 56.5
Other Current Assets 45.6 46.7 92.3
Current Assets 1,198.6 759.5 1,958.1
PPE 449.7 0.0 449.7
Accum D&A -172.2 0.0 -172.2
PPE, Net 277.5 43.7 321.2
Goodwill & Intangibles 520.3 207.6 727.9
Long Term Investments 14.0 15.8 29.8
Other Assets 0.0 0.0 0.0
Other LT Assets 58.1 63.3 121.4
Total Assets 2,068.4 1,090.0 3,158.4
Liabilities
Accounts Payable 82.6 20.1 102.7
Payable/Accrued 0.0 0.0 0.0
Accrued Expenses 104.2 233.1 337.4
ST Debt 0.0 0.0 0.0
Curr Port of LTD & Cap Lease Oblg 8.5 0.1 8.6
Other (Current) Liabilities 40.8 2.0 42.8
Current Liab. 236.1 255.4 491.5
LT Debt 7.4 30.0 37.4
Total LT Debt 7.4 30.0 37.4
Other LT Liab. 60.9 18.4 79.3
Total Liabilities 304.4 303.8 608.2
Shareholders Equity
Common Stock 1.1 0.5 1.6
Additional Paid in Capital 594.9 723.4 1,318.2
Retained Earnings 1,268.9 59.9 1,328.8
Treasure Stock -100.7 0.0 -100.7
Other Equity -0.2 2.5 2.3
Total Equity 1,764.0 786.2 2,550.2
Total Liab. & Equity 2,068.4 1,090.0 3,158.4
Shares Outstanding 106.4 47.4 153.8
Cash Flow
Operating Cash Flow
CF Net Income 211.1 71.6 282.7
CF Depreciation 54.6 8.2 62.8
CF Amortization 0.0 31.0 31.0
CF Deferred Taxes -12.7 -43.3 -56.0
Other Non-Cash Items 41.5 51.1 92.6
Change in Working Capital 133.6 84.3 217.9
Total Cash From Operating Activities 428.0 203.0 631.1
Investing Cash Flow (not calculated)
Capital Expenditures -99.3 -24.6 -123.9
Other Investing Cash Flows -123.4 -15.7 -139.1
Total Cash From Investing Activities -222.7 -40.3 -263.0
Financing Cash Flow (not calculated)
Dividends Paid 0.0 0.0 0.0
Purchase Or Sale of Stock 26.3 24.5 50.7
Purchase and Retirement of Debt -1.1 29.9 28.7
Other Financing Cash Flow 12.7 4.1 16.8
Total Cash From Financing Activities 37.9 58.4 96.3
Exchange Rate Effects 0.0 0.0 0.0
Net Change in Cash 243.2 221.1 464.4
Cash Taxes Paid 130.2 15.3 145.5
Cash Interest Paid 0.5 0.7 1.1